AOD-9604 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
integral polytopic protein Also transmembrane protein. Any of a class of integral membrane proteins which span the entirety of the cell membrane, extending from the interior or cytosolic side of the membrane to the exterior or extracellular side. Transmembrane proteins typically have hydrophilic domains exposed to each side as well as one or more hydrophobic domains crossing the nonpolar space inside the lipid bilayer, by which they are further classified as single-pass or multipass membrane proteins. As such many transmembrane proteins function as gated channels or transporters to permit or prohibit the movement of specific molecules or ions across the membrane, often undergoing conformational changes in the process, or as receptors in cell signaling pathways. Contrast integral monotopic protein.
=== Protein unfolding and aggregation === HClO is known to cause post-translational modifications to proteins, the notable ones being cysteine and methionine oxidation. A recent examination of HClO's bactericidal role revealed it to be a potent inducer of protein aggregation. Hsp33, a chaperone known to be activated by oxidative heat stress, protects bacteria from the effects of HClO by acting as a holdase, effectively preventing protein aggregation. Strains of Escherichia coli and Vibrio cholerae lacking Hsp33 were rendered especially sensitive to HClO. Hsp33 protected many essential proteins from aggregation and inactivation due to HClO, which is a probable mediator of HClO's bactericidal effects.
In March 2018 Heseltine expressed concern over Theresa May's Brexit negotiations, commenting: "Why is it that after 18 months since the referendum we have not got any closer with these issues? The answer is simple: because no one has got any answer about how to do it." He also said the gulf between what May wanted and what the EU was willing to give was not narrowing and may be widening, adding "While that gap remains industry will continue to make assumptions that will involve moving investment from here to the continent. (...) The downsides are becoming more evident as time passes. We have had a serious devaluation of the currency. We have turned ourselves from the fastest growing to the slowest growing economy in Europe and we have made a complete Horlicks of the Irish border. I am totally with the view of Tony Blair and John Major that this matter has got to go back to parliament and possibly to a referendum or a general election." Heseltine was one of the signatories of a statement by senior Conservatives calling for a second referendum over Brexit. This stated, "If we are to remain a party of government, it is absolutely critical that we increase our support among younger generations. To do this, we must listen to and engage with their concerns on Brexit. They voted overwhelmingly to Remain in the European Union in 2016 – and since then have become even stronger in their views. Since the referendum, nearly 2 million young people are now of voting age.
== Ex vivo or in vivo methods == Methods that screen protein–protein interactions in the living cells. Bimolecular fluorescence complementation (BiFC) is a technique for observing the interactions of proteins. Combining it with other new techniques, dual expression recombinase based (DERB) methods can enable the screening of protein–protein interactions and their modulators. The yeast two-hybrid screen investigates the interaction between artificial fusion proteins inside the nucleus of yeast. This approach can identify the binding partners of a protein without bias. However, the method has a notoriously high false-positive rate, which makes it necessary to verify the identified interactions by co-immunoprecipitation.
Polling indicated that the majority of voters support a ceasefire and American mediation in the Gaza war. According to a YouGov poll in March 2024, 52% of Americans supported stopping weapons shipments to Israel, coming largely from Americans who voted for Biden in 2020 (62% support) and people who did not vote in 2020 (60%). 55% of Americans who voted for Trump in 2020 opposed halting weapons shipments, while 30% supported the measure. Republicans generally supported arms to Israel, while Democrats were divided on the issue. Harris largely continued Biden's approach to the Israeli–Palestinian conflict, although she was seen as more sympathetic to Palestinians than Biden or Trump. During the Gaza war, Harris supported Israel's offensive, saying "the threat Hamas poses to the people of Israel must be eliminated". By March 2024, Harris was increasingly critical of Israel, calling for a ceasefire and two-state solution, and opposing the Rafah offensive, though still supporting the war overall. In the Democratic primaries, the Uncommitted National Movement led a protest campaign against Biden and later Harris over the war, calling for a ceasefire and arms embargo on Israel. It received over 700,000 votes and 36 delegates. Harris engaged with Uncommitted and Arab-American leaders, but refused to change her position. Harris argued for continued weapons shipments to Israel, saying it had a right to defend itself. Uncommitted ultimately encouraged its supporters to vote for Harris, though many were reluctant.
Sources: en.wikipedia.org
=== EC 1.4.3 With oxygen as acceptor === EC 1.4.3.1: D-aspartate oxidase EC 1.4.3.2: L-amino-acid oxidase EC 1.4.3.3: D-amino-acid oxidase EC 1.4.3.4: monoamine oxidase EC 1.4.3.5: pyridoxal 5′-phosphate synthase EC 1.4.3.6: replaced by two enzymes, EC 1.4.3.21 (primary-amine oxidase) and EC 1.4.3.22 (diamine oxidase) EC 1.4.3.7: D-glutamate oxidase EC 1.4.3.8: ethanolamine oxidase EC 1.4.3.9: Now included with EC 1.4.3.4 amine oxidase (flavin-containing) EC 1.4.3.10: putrescine oxidase EC 1.4.3.11: L-glutamate oxidase EC 1.4.3.12: cyclohexylamine oxidase EC 1.4.3.13: protein-lysine 6-oxidase EC 1.4.3.14: L-lysine oxidase EC 1.4.3.15: D-glutamate(D-aspartate) oxidase EC 1.4.3.16: L-aspartate oxidase EC 1.4.3.17: Now EC 1.3.3.10, tryptophan α,β-oxidase EC 1.4.3.18: Not approved as the enzyme was shown to be a dehydrogenase and not an oxidase (see EC 1.5.99.12, cytokinin dehydrogenase) EC 1.4.3.19: glycine oxidase EC 1.4.3.20: L-lysine 6-oxidase EC 1.4.3.21: primary-amine oxidase EC 1.4.3.22: diamine oxidase EC 1.4.3.23: 7-chloro-L-tryptophan oxidase EC 1.4.3.24: Now EC 1.4.2.3, pseudooxynicotine oxidase EC 1.4.3.25: L-arginine oxidase EC 1.4.3.26: pre-mycofactocin synthase
== Treatment == Conservative treatment of craniocervical instability includes physical therapy and the use of a cervical collar to keep the neck stable. Cervical spinal fusion is performed on patients with more severe symptoms.
The study of action potentials has required the development of new experimental methods. The initial work, prior to 1955, was carried out primarily by Alan Lloyd Hodgkin and Andrew Fielding Huxley, who were, along John Carew Eccles, awarded the 1963 Nobel Prize in Physiology or Medicine for their contribution to the description of the ionic basis of nerve conduction. It focused on three goals: isolating signals from single neurons or axons, developing fast, sensitive electronics, and shrinking electrodes enough that the voltage inside a single cell could be recorded. The first problem was solved by studying the giant axons found in the neurons of the squid (Loligo forbesii and Doryteuthis pealeii, at the time classified as Loligo pealeii). These axons are so large in diameter (roughly 1 mm, or 100-fold larger than a typical neuron) that they can be seen with the naked eye, making them easy to extract and manipulate. However, they are not representative of all excitable cells, and numerous other systems with action potentials have been studied. The second problem was addressed with the crucial development of the voltage clamp, which permitted experimenters to study the ionic currents underlying an action potential in isolation, and eliminated a key source of electronic noise, the current IC associated with the capacitance C of the membrane. Since the current equals C times the rate of change of the transmembrane voltage Vm, the solution was to design a circuit that kept Vm fixed (zero rate of change) regardless of the currents flowing across the membrane.
Alpha Oumar Barry – Medical doctor and politician, former Minister of State for Exchange, Guinea Folly Bah Thibault - French Guinean journalist, and senior presenter for Al Jazeera English, Founder of Elle Ira à l’Ecole. Ousmane Baldé – Economist and politician. former governor of Guinean Fed reserve (Central bank), former minister of finance. Guinea M'Mahawa Sylla - First female general of the Guinean Armed Forces, Governor of Conakry. Khaité Sall (in French - Minister of Health, Guinea Kaba Rougui Barry - Minister of Pre-University, Technical, Vocational Education and Civic Education, Mayor of Matam, first female mayor in Guinea. Aissatou Baldé - former minister of youth and youth employment. Moustapha Mamy Diaby - former Minister of Mail, Telecommunications and the digital Economy, Guinea. Mamadou Boye Bah – Politician and economist, former president of Union for the New Republic and former president of Union of Democratic Forces of Guinea. Siradiou Diallo – Journalist and politician, former magazine Jeune Afrique Editor in chief, and former president of Union for Progress and Renewal (Guinea). Cellou Dalein Diallo – Economist and politician, former Minister and prime minister; Opposition Leader, Guinea Tierno Monénembo (real name Thierno Saidou Diallo) – novelist and biochemist, winner of the Prix Renaudot award in 2008 for his novel The King of Kahel, winner of Grand Prix de la Francophonie 2017. Guinea Djibril Tamsir Niane – Guinean historian, playwright and short story writer. Alpha Bacar Barry - Minister of Higher Education, Scientific Research and Innovation.
=== Laboratory validity === To date, most published testing has been run in an unvalidated, unreportable manner. The ‘standard microbiological testing’ that samples are subjected to prior to metagenomics is variable and has not included reverse transcription-polymerase chain reaction (RT-PCR) testing for common respiratory viruses or, routinely 16S/ITS PCR testing. Given the relative costs of validating and performing metagenomic versus 16S/ITS PCR testing, the second one is considered an easier and more efficient option. A potential exception to the 16S/ITS testing is blood, given the huge amount of 16S sequence available, making clean cutoffs for diagnostic purposes problematic. Furthermore, almost all of the organisms detected by metagenomics for which there is an associated treatment and thus would be truly actionable are also detectable by 16S/ITS testing (or 16S/ITS-NGS). This makes questionable the utility of metagenomics in many diagnostic cases. One of the main points to accomplish laboratory validity is the presence of reference standards and controls when performing mNGS assays. They are needed to ensure the quality and stability of this technique over time.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.